PE20081185A1 - Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden - Google Patents
Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprendenInfo
- Publication number
- PE20081185A1 PE20081185A1 PE2007000018A PE2007000018A PE20081185A1 PE 20081185 A1 PE20081185 A1 PE 20081185A1 PE 2007000018 A PE2007000018 A PE 2007000018A PE 2007000018 A PE2007000018 A PE 2007000018A PE 20081185 A1 PE20081185 A1 PE 20081185A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- human interleukin
- antibodies
- understand
- compositions
- Prior art date
Links
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 title abstract 3
- 102000019207 human interleukin-13 Human genes 0.000 title abstract 3
- 102000003816 Interleukin-13 Human genes 0.000 title abstract 2
- 108090000176 Interleukin-13 Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229950011485 pascolizumab Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0600488.1A GB0600488D0 (en) | 2006-01-11 | 2006-01-11 | Immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081185A1 true PE20081185A1 (es) | 2008-10-07 |
Family
ID=35997844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000018A PE20081185A1 (es) | 2006-01-11 | 2007-01-09 | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1976881A2 (enExample) |
| JP (1) | JP2009523154A (enExample) |
| KR (1) | KR20080113201A (enExample) |
| CN (1) | CN101370829A (enExample) |
| AR (1) | AR058955A1 (enExample) |
| AU (1) | AU2007204372A1 (enExample) |
| BR (1) | BRPI0706481A2 (enExample) |
| CA (1) | CA2635972A1 (enExample) |
| CR (1) | CR10161A (enExample) |
| EA (1) | EA200801520A1 (enExample) |
| GB (1) | GB0600488D0 (enExample) |
| IL (1) | IL192207A0 (enExample) |
| MA (1) | MA30156B1 (enExample) |
| NO (1) | NO20082767L (enExample) |
| PE (1) | PE20081185A1 (enExample) |
| TW (1) | TW200736274A (enExample) |
| WO (1) | WO2007080174A2 (enExample) |
| ZA (1) | ZA200805526B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| TWI422387B (zh) | 2006-05-25 | 2014-01-11 | Glaxo Group Ltd | 免疫球蛋白 |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2358754A1 (en) * | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Ligands that bind il-13 |
| PE20160653A1 (es) * | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| EA201190275A1 (ru) * | 2009-05-28 | 2012-11-30 | Глаксо Груп Лимитед | Белок, связывающий интерлейкин-13 (il-13) |
| PL3037104T3 (pl) | 2009-10-20 | 2020-11-16 | Abbvie Inc. | Izolacja i oczyszczanie przeciwciał anty-il-13 z zastosowaniem chromatografii powinowactwa z białkiem a |
| JP2013544235A (ja) * | 2010-10-15 | 2013-12-12 | メドイミューン・リミテッド | 肺機能を改善する治療法 |
| KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| EP2686014A1 (en) | 2011-03-16 | 2014-01-22 | Sanofi | Uses of a dual v region antibody-like protein |
| AR098155A1 (es) | 2013-10-23 | 2016-05-04 | Genentech Inc | Métodos para diagnosticar y tratar trastornos eosinofílicos |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用 |
| CN106536754B (zh) | 2014-04-11 | 2021-04-16 | 诺华股份有限公司 | 用il-13拮抗剂选择性治疗哮喘的方法 |
| CN107430117A (zh) | 2015-03-16 | 2017-12-01 | 豪夫迈·罗氏有限公司 | 检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途 |
| EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| EP3572426A4 (en) * | 2017-01-23 | 2020-12-23 | Toyo University | ANTI-BODY ANTI-EPHA2 AND IMMUNOLOGICAL DETECTION OF EPHA2 CALLING ANTI-BODY AUDIT |
| CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理（江苏）有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
| CN107909501B (zh) * | 2017-12-05 | 2020-12-01 | 创新先进技术有限公司 | 气味与行为的关联方法、气味社交方法及装置 |
| PE20211304A1 (es) | 2018-02-09 | 2021-07-20 | Genentech Inc | Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| JP2022525703A (ja) * | 2019-03-20 | 2022-05-18 | ジャベリン・オンコロジー・インコーポレイテッド | 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法 |
| GB201919062D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006503018A (ja) * | 2002-08-30 | 2006-01-26 | グラクソ グループ リミテッド | ワクチン |
| WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
| PL1711528T3 (pl) * | 2003-12-23 | 2012-11-30 | Genentech Inc | Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13 |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
-
2006
- 2006-01-11 GB GBGB0600488.1A patent/GB0600488D0/en not_active Ceased
-
2007
- 2007-01-09 TW TW096100833A patent/TW200736274A/zh unknown
- 2007-01-09 PE PE2007000018A patent/PE20081185A1/es not_active Application Discontinuation
- 2007-01-09 AR ARP070100082A patent/AR058955A1/es unknown
- 2007-01-10 EA EA200801520A patent/EA200801520A1/ru unknown
- 2007-01-10 CN CNA2007800022973A patent/CN101370829A/zh active Pending
- 2007-01-10 JP JP2008549873A patent/JP2009523154A/ja active Pending
- 2007-01-10 BR BRPI0706481-0A patent/BRPI0706481A2/pt not_active IP Right Cessation
- 2007-01-10 WO PCT/EP2007/050219 patent/WO2007080174A2/en not_active Ceased
- 2007-01-10 CA CA002635972A patent/CA2635972A1/en not_active Abandoned
- 2007-01-10 KR KR1020087019555A patent/KR20080113201A/ko not_active Withdrawn
- 2007-01-10 AU AU2007204372A patent/AU2007204372A1/en not_active Abandoned
- 2007-01-10 EP EP07703766A patent/EP1976881A2/en not_active Withdrawn
-
2008
- 2008-06-16 IL IL192207A patent/IL192207A0/en unknown
- 2008-06-16 NO NO20082767A patent/NO20082767L/no not_active Application Discontinuation
- 2008-06-24 ZA ZA200805526A patent/ZA200805526B/xx unknown
- 2008-07-11 MA MA31108A patent/MA30156B1/fr unknown
- 2008-07-17 CR CR10161A patent/CR10161A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200805526B (en) | 2009-10-28 |
| AU2007204372A1 (en) | 2007-07-19 |
| CA2635972A1 (en) | 2007-07-19 |
| CN101370829A (zh) | 2009-02-18 |
| WO2007080174A3 (en) | 2007-12-06 |
| EA200801520A1 (ru) | 2009-02-27 |
| KR20080113201A (ko) | 2008-12-29 |
| GB0600488D0 (en) | 2006-02-22 |
| TW200736274A (en) | 2007-10-01 |
| IL192207A0 (en) | 2008-12-29 |
| BRPI0706481A2 (pt) | 2011-03-29 |
| NO20082767L (no) | 2008-10-06 |
| EP1976881A2 (en) | 2008-10-08 |
| JP2009523154A (ja) | 2009-06-18 |
| MA30156B1 (fr) | 2009-01-02 |
| WO2007080174A2 (en) | 2007-07-19 |
| AR058955A1 (es) | 2008-03-05 |
| CR10161A (es) | 2008-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
| HRP20171690T1 (hr) | Antitijela koja se vežu za humani cgrp receptor | |
| PE20110801A1 (es) | Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f | |
| PE20060376A1 (es) | ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3 | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| RU2011121419A (ru) | Иммуноглобулины | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| PE20120554A1 (es) | Polipeptidos y metodo de tratamiento | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| PE20091342A1 (es) | Inmunoglobulinas | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| PE20130159A1 (es) | Anticuerpos anti-cd40 | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| PE20120211A1 (es) | Anticuerpos que tienen especificidad por ox40 humana | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| PE20081186A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| CO6260104A2 (es) | Anticuerpos contra la il-25 | |
| JP2013091655A5 (enExample) | ||
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| JP2011517447A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |